Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Neven

Showing results (291-300 of 383) with videos related to

Pageof 39
Sort By:
Cancer|December 8, 2020
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trialJose P Leone, Bernard F Cole, Meredith M Regan, et al.
Breast Cancer Research : BCR|January 16, 2021
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancerPeter Schmid, Marie-Paule Sablin, Jonas Bergh, et al.
Nature Communications|November 26, 2025
Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 studyAndreas Papagiannis, Samira Majjaj, Francois P Duhoux, et al.
Breast (Edinburgh, Scotland)|April 23, 2024
Metastases of primary mixed no-special type and lobular breast cancer display an exclusive lobular histologyGitte Zels, Karen Van Baelen, Maxim De Schepper, et al.
European Journal of Cancer (Oxford, England : 1990)|May 29, 2023
Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancerTatjana Geukens, Maxim De Schepper, François Richard, et al.
Journal of the National Cancer Institute|March 8, 2012
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trialMeredith M Regan, Brian Leyland-Jones, Mark Bouzyk, et al.
Journal of Oncology|July 14, 2020
Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in <i>BRCA1/2</i>: A Review of Secondary Prevention GuidelinesBoudewijn Dullens, Robin de Putter, Matteo Lambertini, et al.
Eclinicalmedicine|May 26, 2021
Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnanciesLiesbeth Lenaerts, Nathalie Brison, Charlotte Maggen, et al.
Breast Cancer Research and Treatment|February 16, 2021
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancerAndrew Wardley, Javier Cortes, Louise Provencher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy OutcomesPriya Rastogi, Joyce O'Shaughnessy, Miguel Martin, et al.
Pageof 39

Showing results (291-300 of 383) with videos related to

Sort By:
Pageof 39
Cancer|December 8, 2020
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trialJose P Leone, Bernard F Cole, Meredith M Regan, et al.
Breast Cancer Research : BCR|January 16, 2021
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancerPeter Schmid, Marie-Paule Sablin, Jonas Bergh, et al.
Nature Communications|November 26, 2025
Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 studyAndreas Papagiannis, Samira Majjaj, Francois P Duhoux, et al.
Breast (Edinburgh, Scotland)|April 23, 2024
Metastases of primary mixed no-special type and lobular breast cancer display an exclusive lobular histologyGitte Zels, Karen Van Baelen, Maxim De Schepper, et al.
European Journal of Cancer (Oxford, England : 1990)|May 29, 2023
Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancerTatjana Geukens, Maxim De Schepper, François Richard, et al.
Journal of the National Cancer Institute|March 8, 2012
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trialMeredith M Regan, Brian Leyland-Jones, Mark Bouzyk, et al.
Journal of Oncology|July 14, 2020
Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in <i>BRCA1/2</i>: A Review of Secondary Prevention GuidelinesBoudewijn Dullens, Robin de Putter, Matteo Lambertini, et al.
Eclinicalmedicine|May 26, 2021
Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnanciesLiesbeth Lenaerts, Nathalie Brison, Charlotte Maggen, et al.
Breast Cancer Research and Treatment|February 16, 2021
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancerAndrew Wardley, Javier Cortes, Louise Provencher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy OutcomesPriya Rastogi, Joyce O'Shaughnessy, Miguel Martin, et al.
Pageof 39